Back to Top Skip to main content

DoD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DoD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. 

To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).

DoD P&T Committee Meeting Schedule

View DoD P&T Meeting Minutes See Archived Meeting Pages


November 4-5, 2020

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: July 31, 2020
  • Pre-Proposal Teleconference: August 12, 2020 @ 1300 Central
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: September 18, 2020

 

Class Review Designated Newly Approved Drugs  Drugs in Previously Review Classes
 
  • ADHD AGENTS - STIMULANTS:

    • Adderall
    • Adderal XR
    • Adhansia XR
    • Azdenys ER
    • Adzenys XR ODT
    • Aptensio XR
    • Concerta
    • Cotempla XR ODT
    • Daytrana
    • Desoxyn
    • Dexedrine
    • Dextrostat
    • Dyanavel XR
    • Evekeo
    • Evekeo ODT
    • Focalin
    • Focalin XR
    • Jornay PM
    • Metadate CD
    • Metadate ER
    • Methylin solution, tab chew
    • Methylin ER
    • Mydayis
    • Procentra
    • Quillichew ER
    • Quillivant XR
    • Ritalin
    • Ritalin LA
    • Ritalin SR
    • Vyyanse Capsule
    • Vyvanse Chewable
    • Zenzedi

  • RESPIRATORY INTERLEUKINS - NA
    • Nucala
    • Dupixent
    • Fasenra

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management  actions.  Additionally, if a drug is approved prior to 27 August 2015, but not currently available the committee may still make a formulary recommendation. 

 
  • AirDuo Digihaler
  • ArmonAir Digihaler
  • Bafiertam 
  • Breztri Aerosphere
  • Conjupri 
  • Cystadrops
  • Dojolvi
  • Dupixent Pen
  • Enspryng 
  • Evrysdi
  • Gavreto
  • Gimoti
  • Hemady
  • Inqovi
  • Kesimpta
  • Lampit 
  • Mycapssa
  • Ongentys
  • Onureg
  • Ortikos
  • Rukobia
  • Semglee
  • Sevenfact
  • Upneeq
  • Xywav
 
  • Glumetza 
  • Lexette
  • Vimovo

August 5-6, 2020

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: May 6, 2020
  • Pre-Proposal Teleconference: May 13, 2020 @ 1300 Central
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: June 26, 2020*

 

Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PSORIASIS AGENTS - NA:

    • Calcitriol
    • Calcitrene
    • Calcipotriene Clobetasol
    • Calcipotriene Monohydrate
    • Dovonex
    • Enstilar
    • Oxsoralen-Ultra
    • Soriatane
    • Sorilux
    • Taclonex
    • Tazorac
    • Vectical

  • SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS
    • Nuvigil
    • Provigil
    • Sunosi
    • Wakix
    • Xyrem

  • WHITE BLOOD CELL STIMULANTS - FILGRASTIMS
    • Granix
    • Neupogen
    • Nivestym
    • Zarxio

  • WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIMS
    • Fulphila 
    • Neulasta
    • Udenyca
    • Ziextenzo

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions.  This reflects the delay of the May 2020 P&T meeting Drug Class reviews to August 2020 as noted in the May meeting website posting.  Updated utilization data reflecting the past 3 months has been posted to betasam. 

  • Arazlo
  • Bynfezia
  • Dayvigo
  • Fensolvi
  • Fintepla
  • Halog
  • Isturisa
  • Koselugo
  • Kynmobi
  • Licart
  • Lyumjev
  • Nexlizet
  • Nymalize
  • Oriahnn
  • Pemazyre
  • Phexxi
  • Qinlock
  • Retevmo
  • Tabrecta
  • Tukysa
  • Twirla
  • Zeposia
  • Zilxi
 

 


May 6, 2020

Uniform Formulary Request for Quote Information

  • Uniform Formulary Request for Quote Information (UPDATED 16 Apr 2020)
  • Pre-Proposal Teleconference: February 12, 2020 @ 1300 Central
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: June 26, 2020*

 

Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PSORIASIS AGENTS - NA*                  
  • SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS*
  • WHITE BLOOD CELL STIMULANTS - FILGRASTIMS*
  • WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIMS*

*All May 2020 P&T Drug Class Reviews have been delayed due to the COVID-19 Pandemic.  We expect to review all classes at the August 2020 P&T Meeting.  Please note the new quote solicitation due date of June 26, 2020.  Please contact the RFQ POC with any questions mailto:dha.san-antonio-tx.healthcare-ops.mbx.pharmacy-opsmbxpod-industr@mail.mil.

 
  • Ayvakit
  • Bonsity
  • Caplyta
  • Esperoct
  • Ibrance Tablets
  • Nexletol
  • Nurtec ODT
  • Palforzia
  • Reyvow
  • Riomet ER
  • Tazverik
  • Trijardy XR
  • Ubrelvy
  • Valtoco
  • Xcopri
  • Zerviate
 

February 5-6, 2020

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: November 1, 2019
  • Pre-Proposal Teleconference: November 13 2019 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Quotes Due: December 20, 2019  

 

Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PAIN AGENTS - NSAID:
    • Duexis
    • Qmiiz ODT
    • Sprix
    • Tivorbex
    • Vimovo
    • Vivlodex
    • Zipsor
    • Zorvolex
    • Anaprox DS, generics
    • Ansaid, generics
    • Arthrotec, generics
    • Cambia, generics
    • Cataflam, generics
    • Celebrex, generics
    • Choline magnesium trisalicylate, generics
    • Clinoril, generics
    • Daypro, generics
    • Diflunisal, generics
    • Disalcid, generics
    • Dyloject, generics
    • Feldene, generics
    • Fenortho, generics
    • Ibu, generics
    • Indocin IR, generics
    • Indocin ER, generics
    • Indocin Rectal, generics
    • Indocin Suspension, generics
    • Lodine, generics
    • Lodine XL, generics
    • Meclomen, generics
    • Mobic, generics
    • Nalfon, generics
    • Naprelan CR, generics
    • Naproxen IR, generics
    • Naproxen DR, generics
    • Naproxen Suspension, generics
    • Orudis, generics
    • Oruvail, generics
    • Ponstel, generics
    • Profeno, generics
    • Relafen, generics
    • Tolectin, generics
    • Toradol cartridge, generics
    • Toradol syringe, generics
    • Toradol tablet, generics
    • Toradol vial, generics
    • Voltaren DR, generics
    • Voltaren XR tablet, generics
  • PAIN AGENTS - PAIN TOPICAL:
    • Diclofono
    • Flector, generics
    • Lidoderm, generics
    • Pennsaid drops, generics
    • Pennsaid Pump
    • Voltaren, generics
    • ZTLido
  • Aklief
  • Amzeeq
  • Brukinsa
  • Consensi
  • Enzoclear
  • Fasenra Pen
  • Gloperba
  • Jatenzo
  • Oxbryta
  • Ozobax
  • Pretomanid
  • Proair Digihaler
  • Secuado
  • Talicia
  • Trikafta
  • Vumerity
  • Ziextenzo
 

Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Decision Papers

File Date
Decision Paper on Implementing ESI Commercial Reject List and Prior Authorization for all Compound Medication Prescriptions 5/8/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.